Modified chimeric antigens IBMP 8.1 and 8.3 for the detection and diagnosis of trypanosoma cruzi
Modified chimeric IBMP antigens 8.1 and 8.3, with the addition of the PEP2 peptide, enhance the detection of Trypanosoma cruzi antibodies, addressing the limitations of current diagnostic tests by improving sensitivity and specificity for Chagas disease diagnosis.
Patent Information
- Application Number
- PCT/US2024/027617
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-03
- Filing Date
- 2024-05-03
- Publication Date
- 2024-11-07
AI Technical Summary
Current diagnostic tests for Chagas disease, caused by Trypanosoma cruzi, are limited by low sensitivity and high false positive rates, particularly in veterinary medicine, due to variations in antigen strains and lack of a gold standard for testing, leading to overlooked infections in dogs and humans.
Modified chimeric IBMP antigens 8.1 and 8.3 are developed by inserting the PEP2 peptide, which can be used in combination with other T. cruzi antigens, for enhanced specificity and sensitivity in immunoassays such as lateral flow assays to detect T. cruzi antibodies, providing a more accurate diagnosis.
The modified chimeric antigens significantly improve the accuracy and sensitivity of Chagas disease detection, reducing false positives and enabling efficient diagnosis in both human and animal subjects, overcoming limitations of existing tests.
Smart Images

Figure US2024027617_07112024_PF_FP_ABST
Abstract
Description
[0001] MODIFIED CHIMERIC ANTIGENS IBMP 8.1 AND 8.3 FOR THE DETECTION AND DIAGNOSIS OF TRYPANOSOMA CRUZI CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of US Provisional Application Ser. No. 63 / 463,649, filed May 3, 2023, the disclosure of said application being incorporated herein in its entirety. FIELD The presently disclosed subject matter relates in general to the use of a modified chimeric IBMP antigen in the detection of the parasite Trypanosoma cruzi, and more particularly to the preparation and use of modified chimeric IBMP antigens 8.1 and 8.3 for detecting the presence of Trypanosoma cruzi and diagnosing a Chagas disease infection in human and animal subjects. The modified chimeric IBMP 8.1 and 8.3 antigens of the disclosure are modified by the addition or insertion of the PEP2 peptide therein, and the PEP2 antigen may be added along with other suitable antigens or fragments from T. cruzi, and these modified chimeric antigens can be used in immunoassays such as a lateral flow assay so as to provide a highly accurate method of detecting T. cruzi antibodies in human or animal subjects and for diagnosing a Chagas disease infection in those subjects. BACKGROUND Among several illnesses common to pets such as dogs that can also affect humans, American trypanosomiasis, commonly known as Chagas disease, is a parasitic condition caused by the hemoflagellated protozoa, Trypanosoma cruzi. Active transmission is through triatomine vectors known as kissing bugs, which are prevalent in North and South America. Defecation by infected insects during or after a blood meal passes infective trypomastigotes into the bite wound. Other routes of infection include transplacental transmission to offspring of infected pregnant humans and animals, consumption of a variety of infected foods such as juices and meats that have been tainted by the parasite and are contaminated with triatomine feces. Another source of these illnesses are blood transfusion from other patients that have not been screened for such parasites. After trypomastigotes enter the circulation, there is a brief period of replication and hematogenous spread through mononuclear cells, with the final destination being various tissues in the host, including the heart, fat, and the lymphatic system, where they reside and multiply as intracellular amastigotes. A century after its discovery, T. cruzi infection remains a serious health problem in humans and animals. It is a leading cause of cardiomyopathy that affects over 8 million people worldwide, and it is predicted that Chagas disease will cause at least 200,000 human deaths globally over the next 5 years, which is identical to the number of women living in the United States predicted to die of breast cancer in the same time period. Whereas the highest prevalence of cardiomyopathy due to Chagas disease in people is found in Central and South American countries, studies show a widespread distribution of American trypanosomiasis in dogs in Texas, Louisiana, and Georgia and indicate that these southern states are the sites of important reservoirs for transmission of Trypanosoma cruzi in the United States. The prevalence of T. cruzi infection in stray and shelter-housed dogs has been reported to be as high as 7.5% to 8.8% and may exceed 50% in some working dog kennels in Texas. The pattern of disease progression in dogs with American trypanosomiasis is similar to that in people, which comprises acute, chronic asymptomatic, and chronic symptomatic phases. Acute disease occurs within 3 weeks after inoculation and centers around myocarditis with severe inflammation following the death of cardiac cells.16,17 Most affected dogs are < 1 year of age, and clinical signs commonly include tachyarrhythmias, respiratory distress, lymphadenopathy, anorexia, diarrhea, neurologic abnormalities, peripheral edema, collapse, and sudden death. Parasitemia is profound and the mortality rate is high, especially among < 1-year-old dogs. Unfortunately, the detection and treatment of Chagas diseases remains limited due to barriers and shortcomings of current diagnostic tests. In particular, Chagas disease diagnosis in veterinary medicine is currently limited commercially to antibody detection using IFA. This is an old technology using whole epimastigote antigen from the vector. While this is helpful in diagnosing antibody in the patient, it lends itself to false negatives due to variation in antigen across multiple strain types in the world. There is no gold standard to test for T. cruzi infections in dogs, and the IFA is the only test approved for veterinary Chagas diagnostics. Current literature in assessing attempts in this field continue to echo the need for a more sensitive tests of Chagas disease that are accurate and avoid false positives that can occur due to cross- reactivity of many T. cruzi antigens. In more recent testing, some in the field focused on chimeric antigens arising from T. cruzi peptides, including repetitive epitopes such as LA204, IBMP 8.1 and IBMP 8.4. Although some of these chimeric antigens were considered to have promise in detecting T. cruzi antibodies, the tests were inconsistent, and n certain tests, the IBMP antigen 8.3 was the least suitable in terms of providing accurate results with regard to identifying T. Cruzi infections without also testing positive for other possible parasitic infections. Because of the lack of suitable accurate testing, Chagas infection in dogs is often overlooked in veterinary medicine, and despite a large prevalence in the U.S., there is currently no definitive testing protocol that can be carried out in an efficient manner and yet have the high accuracy necessary to achieve a satisfactory test that does not suffer from false positive results. There is thus a desperate need for a convenient and sensitive for symptomatic and asymptomatic pet populations for Chagas disease that can provide highly accurate results and avoid false positives. SUMMARY The present invention relates to a modified chimeric IBMP antigen for use in detecting the parasite Trypanosoma cruzi in human and animal subjects with greater accuracy and fewer false positive tests. In this modified chimeric IBMP antigen, the antigens IBMP 8.1 and 8.3 are modified for use in detecting the presence of Trypanosoma cruzi in order to diagnose Chagas disease in a human or animal patient, and the modification may be obtained by inserting the PEP2 peptide and optionally other T. cruzi antigens into the IBMP 8.1 and / or 8.3 antigens, and using the modified antibodies to detect the presence of antibodies to T. cruzi in human and animal patients. An IBMP 8.4 antigen is used along with the modified 8.1 and 8.3 antigens. The modified chimeric antigens including the modified IBMP 8.1 and 8.3 antigens along with IBMP 8.4 may be used in a lateral flow assay or other suitable assays for the detection of T. cruzi and the diagnosis in a human or animal patient of a Chagas disease infection. Test kits employing these chimeric antigens are also provided as described further below. In one exemplary aspect of the present invention a chimeric antigen is provided which comprises a modified IBMP 8.1 antigen and / or a modified IBMP 8.3 antigen, wherein either of both of the modified IBMP 8.1 and / or 8.3 antigens contain at least one PEP2 antigen inserted therein. The PEP2 may be inserted in the modified chimeric IBMP 8.1 and / or 8.3 antigens in any suitable location where it will supplement the antigenic effect of the IBMP protein and will provide a more accurate and sensitive test for the presence of T. cruzi antigens in human and animal patients. Insertions of PEP2 can be at a variety of locations, such as in many of the specific regions of the IBMP 8.1 and 8.3 antigens as described herein. Specific examples are provided below wherein the modified IBMP 8.1 antigen has amino acid sequence SEQ ID NO: 1 or SEQ ID NO: 2, and other suitable examples are provided wherein the modified IBMP 8.3 antigen of the invention has an amino acid sequence that is selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6. Still other suitable forms of PEP2 insertion within the present invention are possible as would be understood by those of ordinary skill in the art. In these embodiments, the modified 8.1 and 8.3 IBMP antigens may contain one PEP2 antigen or a plurality of PEP2 antigens as needed to maximize the usefulness of these antigens in forming an efficient and highly accurate testing assay for T. cruzi antibodies and infections of Chagas diease in human and animal patients. In another exemplary embodiment, a chimeric antigen for diagnosing a Chagas disease infection is provided wherein the chimeric antigen comprises a modified IBMP 8.1 antigen and a modified IBMP 8.3 antigen, wherein the modified IBMP 8.1 and 8.3 antigens contain at least one PEP2 antigen. As indicated below, in the antigenic composition of the invention, this construct may also include an unmodified IBMP 8.4 antigen in combination with the modified IBMP 8.1 and 8.3 antigens as described herein. In still further exemplary embodiments, a chimeric antigen for diagnosing a Chagas disease infection is provided wherein the chimeric antigen comprises a modified IBMP 8.1 antigen and an unmodified IBMP 8.3 antigen, wherein the modified IBMP 8.1 chimeric antigen contains at least one PEP2 antigen. In addition, a chimeric antigen for diagnosing a Chagas disease infection is provided wherein the chimeric antigen comprises a modified IBMP 8.3 antigen and an unmodified IBMP 8.1 antigen, wherein the modified IBMP 8.3 chimeric antigen contains at least one PEP2 antigen. As indicated below, in the antigenic compositions of the invention, this construct may also include an unmodified IBMP 8.4 antigen in combination with the modified IBMP 8.1 and 8.3 antigens as described herein. In an additional exemplary embodiment of the present invention, there is provided a chimeric antigen for use in diagnosing a Chagas disease infection that comprises a modified IBMP 8.1 antigen and / or a modified IBMP 8.3 antigen, and the modified 8.1 and / or 8.3 antigens include at least one PEP2 antigen as set forth above and may also be combined with an unmodified IBMP 8.4 antigen. In certain embodiments, the IBMP 8.4 antigen will have the amino acid sequence of SEQ ID NO: 7. In another exemplary embodiment, the chimeric antigen of the invention for use in diagnosing a Chagas disease infection may be provided which comprises a modified IBMP 8.1 antigen and a modified IBMP 8.3 antigen, wherein the modified IBMP 8.1 and 8.3 antigens contain at least one PEP2 antigen and a second antigen from T. cruzi, such as an antigen selected from the group consisting of 1F8, rTc24 (PGR24- His), TcF, SAPA, TSSA, SAPA / TSSA, SAPA / TSSA, FRA, B13, MACH (PEP2, TcD, TcE, SAPA), TcD, and TcE antigens. In certain embodiments, the second antigen has a sequence selected from the group consisting of SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:14. In other embodiments, the chimeric antigen may comprise modified IBMP 8.1 and 8.3 antigens and an unmodified IBMP 8.4 antigen, wherein the modified IBMP 8.1 and 8.3 antigens contain at least one PEP2 antigen and a second antigen selected from the group consisting of 1F8, rTc24 (PGR24-His), TcF, SAPA, TSSA, SAPA / TSSA, SAPA / TSSA, FRA, B13, MACH (PEP2, TcD, TcE, SAPA), TcD, and TcE antigens. As indicated above, in exemplary embodiments, the modified IBMP 8.1 antigen may have the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2, and the modified IBMP 8.3 antigen may have an amino acid selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6. In certain embodiments the PEP2 antigen may have the amino acid sequence of SEQ ID NO: 7. In another exemplary embodiment of the present invention, an immunoassay for detecting the presence or absence of antibodies against Trypanosoma cruzi is provided which comprises the chimeric antigen as described above which includes a modified 8.1 and / or 8.3 antigen containing a PEP2 antigen inserted therein along with immunobinding detection reagents which provide a signal that indicates immunobinding when an antibody against Trypanosoma cruzi binds with said chimeric antigen. Such an immunoassay may be selected from the group consisting of lateral flow immunoassay, multiple antigen blot assay, direct or indirect Enzyme-linked immunosorbent assay (ELISA), enzymatic immunoassay, sandwich assay, electrochemilumescence assay, dipstick immunoassay, and radioisotope assay. In an alternative embodiment, the chimeric antigen of the immunoassay may be constructed to include a modified 8.1 and / or 8.3 antigen containing a PEP2 antigen inserted therein along with an unmodified IBMP 8.4 antigen. As also indicated herein, the chimeric antigen for diagnosing a Chagas disease infection in accordance with the invention may comprise a modified IBMP 8.1 antigen and an unmodified IBMP 8.3 antigen, wherein the modified IBMP 8.1 chimeric antigen contains at least one PEP2 antigen. In addition, a chimeric antigen for diagnosing a Chagas disease infection is provided wherein the chimeric antigen comprises a modified IBMP 8.3 antigen and an unmodified IBMP 8.1 antigen, wherein the modified IBMP 8.3 chimeric antigen contains at least one PEP2 antigen. The chimeric antigen as described herein can then be combined with immunobinding detection reagents which provide a signal that indicates immunobinding when an antibody against Trypanosoma cruzi binds with said chimeric antigen so as to form a suitable immunoassay in accordance with the invention. The immunoassay may be a lateral flow immunoassay or any of a number of conventional immunoassays well known in the art. In use, the immunoassay is used to receive a sample of a bodily fluid or other biological matrix from a human or animal subject or patient that is undergoing to determine if antibodies to T. cruzi are present, and the sample will travel through the immunoassay to a detection region that includes the immunobinding reagents as set forth above which can generate a signal indicative of binding of the antigens in the immunoassay with antibodies from T. cruzi that are present in the sample. In other suitable embodiments, the immunobinding detection reagents of the immunoassay of the invention may comprise those reagents which generate a signal that indicates immunobinding when an antibody against Trypanosoma cruzi binds with said chimeric antigen. The signal used in the present immunoassay can be any appropriate materials that will provide a visual or other identification indicating that immunobinding has taken place and that the antibodies to T. cruzi are present in the sample from the subject. The signal itself can be any conventional signal used in diagnostic assays including a signal selected from the group consisting of a colorimetric signal, a fluorescent signal, a chemiluminescent signal, a radioactive signal, and a visual signal. In one exemplary embodiment, the present immunoassay will be a lateral flow immunoassay capable of detecting the presence or absence of antibodies against Trypanosoma cruzi, and this lateral flow assay can include the modified chimeric antigens as set forth above. In certain embodiments, the modified chimeric antigen used in the lateral flow immunoassay of the invention may be an IBMP chimeric antigen 8.1 and / or a modified IBMP chimeric antigen 8.3 that is modified by adding at least one PEP2 antigen. In alternate embodiments, the modified chimeric antigen in this lateral flow immunoassay may be an IBMP chimeric antigen 8.1 and / or a modified IBMP chimeric antigen 8.3 that each include at least one PEP2 antigen inserted therein combined with an unmodified IBMP 8.4 chimeric antigen as is described further herein. In still further embodiments, in addition to the PEP2 antigen, the modified chimeric antigens of the invention may also include a second T. cruzi antigen, including those antigens selected from the group consisting of consisting of 1F8, rTc24 (PGR24-His), TcF, SAPA, TSSA, SAPA / TSSA, SAPA / TSSA, FRA, B13, MACH (PEP2, TcD, TcE, SAPA), TcD, and TcE antigens. In another exemplary embodiment of the invention, an immunoassay method is provided for detecting the presence or absence of antibodies against Trypanosoma cruzi in a human or animal subject wherein the immunoassay method comprises providing the modified chimeric antigen as described above which contains at least one PEP2 antigen inserted into a modified IBMP 8.1 chimeric antigen and / or a modified IBMP 8.3 chimeric antigen. The modified chimeric antigen of the invention will be used to determine whether a human or animal patient tests positive for the presence of T. cruzi antibodies, so a sample from the human or animal patient is obtained for use of the method. A suitable sample is obtain from a bodily fluid or other biological matrix from the patient, and this sample is contacted with the modified chimeric antigen as described above. In an exemplary method, the detection of T. cruzi antibodies is carried out by contacting said sample with said modified chimeric antigen of the invention; and then determining the presence or absence of antibodies against Trypanosoma cruzi by detecting immunobinding of said chimeric antigen to Trypanosoma cruzi im sa1d sample. In an alternate embodiment, the modified 8.1 and 8.3 antigens can be combined with an unmodified IBMP 8.4 antigen so as to provide the chimeric antigenic composition used in the immunoassay method of the present invention. This immunoassay method may be carried out in any suitable immunoassay form, such as an immunoassay selected from the group consisting of lateral flow immunoassay, multiple antigen blot assay, direct or indirect Enzyme-linked immunosorbent assay (ELISA), enzymatic immunoassay, sandwich assay, electrochemilumescence assay, dipstick immunoassay, and radioisotope assay. In another exemplary embodiment, the modified chimeric antigens IBMP 8.1 and 8.3 antigens can be used in a method of diagnosing a Chagas disease infection in a human or animal subject. In such a method, there is provided the modified chimeric antigens IBMP 8.1 and 8.3 antigens as described above wherein each of said chimeric antigens contain at least one PEP2 antigen embedded therein. In this exemplary method, a sample is obtained from a human or animal patient, such as a bodily fluid or other biological matrix, and this sample is placed in contact with the modified chimeric antigen of the invention, such as on a test strip in an immunoassay; such as a lateral flow immunoassay. By virtue of contacting the sample with the modified chimeric antigen of the invention, the presence or absence of antibodies against Trypanosoma cruzi is determined by detecting immunobinding of the chimeric antigen to Trypanosoma cruzi antibodies in the sample, and the presence of such antibodies are indicative that the human or animal patient is infected with Chagas disease. As indicated above, such a method can be conducted as a lateral flow immunoassay, but numerous other forms of immunoassays may be employed, including multiple antigen blot assays, direct or indirect Enzyme-linked immunosorbent assays (ELISA), enzymatic immunoassays, sandwich assays, electrochemilumescence assays, dipstick immunoassays, and radioisotope assays. An alternative immunoassay method of detecting or diagnosing a Chagas disease infection in a human or animal subject is also provided wherein the modified chimeric antigens used include a modified IBMP 8.1 antigen and a modified 8.3 antigen, both of which will include PEP2 antigens implanted therein, and also will include an unmodified IBMP 8.4 antigen. As in the method described above, the modified chimeric antigen is provided, such as on a test strip, and a sample of bodily fluid or other biological matrix from a human or animal subject is obtained and contacted with this modified chimeric antigen. Any resulting immunobinding to the antigen reflects that there are T. cruzi antibodies in the sample and that the human or animal being testing is infected with Chagas disease. The immunobinding of said chimeric antigen to Trypanosoma cruzi im sa1d sample can be determined by any suitable reagents that can emit an observable In another aspect of the present invention, a test strip is provided that can be utilized for qualitatively determining the present or absence of antibodies against Trypanosoma cruzi which will be indicative of a Chagas disease infection. Such a test strip may be made of a nitrocellulose membrane or other materials which will allow flow through the test strip, such as by capillary action, so that a sample at one end of the strip will migrate through the strip wherein the sample can be contacted by the modified chimeric antigens of the invention, and so that a detection zone is present on the test strip wherein a signal reflecting that immunobinding has occurred between the modified chimeric antigens on the test strip and the antibodies in the sample. As indicated above, the antigen composition used on said test strip may comprise a modified IBMP 8.1 antigen and a modified IBMP 8.3 antigen which both include at least one PEP2 antigen inserted therein. These two antigens may also be combined with an unmodified IBMP 8.4 chimeric antigen in the antigenic composition used in the present invention. Such test strips may be used alone or in cassettes or other devices wherein multiple test strips may be used at the same time. In another exemplary embodiment of the present invention, an immunoassay device is provided for conducting an immunoassay of antibodies against T. cruzi in a human or animal subject. The device comprises a test strip that is pre-coated with the modified chimeric antigen of the invention that comprises modified chimeric IBMP antigens 8.1 and 8.3, each having one or more PEP2 antigens inserted therein. In certain embodiments, the antigenic mix in the test strip of the device may also include an IBMP chimeric antigen 8.4. This immunoassay device of the invention also includes a detection reagent that detects binding between said modified chimeric antigens on the test strip and an antibody against T. cruzi located in a bodily fluid or other biological matrix sample obtained from human or animal subject. The test strip may be comprised of a nitrocellulose membrane, or other suitable materials well known in the field that are used that undergo capillary or wicking action so that when a fluid is introduced at one end of the test strip, that fluid will laterally flow up the test strip so that any antibodies in the sample can combined with the pre-coated modified chimeric antigen as described herein. In one embodiment, the detection reagents generate a signal that indicates that binding of antibodies in the sample and the antigens on the test strip has been detected. Such a signal may be any suitable signal that can be observed either visually or in another form, and such signals can include a colorimetric signal, a fluorescent signal, a chemiluminescent signal, a radioactive signal, and a visual signal. In further embodiments of the present invention, a test kit for qualitatively detecting the presence or absence of antibodies against Trypanosoma cruzi in a sample of bodily fluid or other biological matrix from a human or animal is provided which comprises a modified chimeric antigen as described herein that comprises modified chimeric IBMP antigens 8.1 and 8.3 that have one or more PEP2 antigens inserted therein. In additional embodiments, the chimeric IBMP antigen 8.4 may also be used. In one embodiment, in addition to the modified chimeric antigen as described above, the test kit will also a test strip wherein the antigens can be located and immunobinding detection reagents that can be added to the test strip so as to provide a signal indicative of immunobinding of said chimeric antigen when the sample contains antibodies against Trypanosoma cruzi. In certain embodiments, the test strip will have a particular detection zone included therein wherein the signal indicative of immunobinding of said chimeric antigen on the test strip and Trypanosoma cruzi antibodies in the sample can be observed. The kit may also include devices such as a swab which collect the sample from a patient to be tested, and the sample can be a bodily fluid or other biological matrix from the patient. Suitable samples may be a bodily fluid, serum, whole blood, saliva, and / or other biological matrices. In the operation of the test kit, a sample is obtained from a human or animal patient being tested, such as by a cotton swab or other suitable device, and the sample may be placed in a buffer solution that may also be included in the test kit. Once the sample is obtained and placed into the buffer, solution a certain amount of the solution is then applied to the test strip so that the fluid will migrate from the application point through the test strip so that it can mix with the modified chimeric antigens in the test strip, and then reach a detection zone wherein a signal is generated (or not generated) that reflects presence or absence of T. cruzi antibodies in the sample obtained from the patient. Still further, the invention provides an immunoassay system for qualitatively detecting the presence or absence of antibodies against Trypanosoma cruzi in a human or animal subject that comprises the modified chimeric antigens 8.1 and 8.3 above, with or without an unmodified 8.4 IBMP antigen. These antigens may be located on a test strip to which is applied a sample of bodily fluid or other biological matrix from the human or animal subject that can be applied to said test strip. The system also includes an immunobinding detection reagent that will normally be located on said test strip and which provide a signal that indicates immunobinding of the antigens when the sample contains antibodies against Trypanosoma cruzi, and there is a detection zone on said test strip wherein the signal indicative of immunobinding between the antigens on the test strip and antibodies against Trypanosoma cruzi can be observed. The signal generated by virtue of the immunobinding may be selected from the group consisting of a colorimetric signal, a fluorescent signal, a chemiluminescent signal, a radioactive signal, and a visual signal. The test strip may be made of a nitrocellulose membrane but can also be any suitable material which undergoes capillary action so that a fluid sample can migrate laterally through the test strip and that antibodies in the sample may bind with the antigens on the test strip. The antigens, compositions, methods, systems, test strips, kits, and other aspects of the present invention using the modified chimeric antigen as described herein for the qualitative determination of the presence of the T. cruzi parasite that causes Chagas disease in humans and animals are further described below . BRIEF DESCRIPTION OF THE DRAWING FIGURE Figure 1 is a schematic view of the orientation and the components of an exemplary immunoassay in accordance with the present invention. DETAILED DESCRIPTION OF EXEMPLARY EMBODIMENTS The present invention relates to the field of veterinary diagnostics, specifically to a test for the rapid detection of antibodies against human and animal infectious parasitic diseases such as Chagas disease. The purpose of this invention is to provide a greatly enhanced method of detection of antigens by antibodies against T. Cruzi, the parasite that causes Chagas disease. In this case, an antigen is a protein that is expressed by the T. Cruzi parasite that will generate antibodies in a human or animal subject exposed to T. Cruzi. When the antigens are bound to an anti-T. Cruzi antibody, such binding can be detected by a variety of diagnostic assays. However, there are limitations in using antigens to detect parasitic diseases such as Chagas disease, including the fact that certain antigens may be non-specific, namely that may be recognized by antibodies present in a bodily fluid, but those antibodies might have been generated by virtue of exposure to a different parasite. Accordingly, it has constantly been a goal to develop more accurate immunoassay testing devices that have a higher percentage of identifying the desired parasite and less likely to indicate false positive results. In accordance with the present invention, the inventors have discovered that the additional of particular antigens and / or antigen fragments to an existing chimeric antigen can greatly improve the sensitivity, specificity, and accuracy of an assay by increasing the number of proteins expressed by the T. cruzi parasite presented to human or animal anti-T. Cruzi antibodies. This will greatly increase the likelihood of accurate recognition by the circulating antibodies in mammalian whole blood or serum. At the same time, as indicated above, the addition of particular antigens or fragments thereof has to be very carefully approached so as to not include those antigens or fragments that may be recognized by non-T. cruzi parasites. As a result, there is still a need for improving sensitivity and specificity of diagnostics designed to detect T. cruzi above the current commercially available assays such as Indirect Fluorescent Antibody Assay (IFA) or Polymerase Chain Reaction (PCR) Assays. One area that has been examined with regard to antigens that may be useful in detection of T. cruzi antibodies have been the IBMP chimeric proteins 8.1, 8.2, 8.3, and 8.4 that have been examined in a series of experiments dealing with recognition of these antigens. However, in some cases, the results varied, and some testing even appeared to show that IBMP chimeric antigen 8.3 was less efficient in recognition. These chimeric antigens constitute different combined antigenic regions from T. cruzi, and the regions from IBMP chimeric antigens 8.1- 8.4 have been characterized and sequenced as reflected below: Table 1 – Regions of IBMP Chimeric Antigens 8.1-8.3 Table 2 – Regions of IBMP Chimeric Antigen 8.4 Previously, IBMP chimeric antigens 8.1, 8.2, 8.3, and 8.4 have been examined in a series of experiments dealing with recognition of these antigens. However, in some cases, the results varied, and some testing appeared to show that IBMP chimeric antigen 8.3 was less efficient in recognition than the other IBMP antigens. These chimeric antigens constitute different combined antigenic regions from T. cruzi, and the regions from IBMP chimeric antigens 8.1-8.4 have been characterized and sequenced as reflected below: In reviewing the sequences of the various chimeric IBMP 8.1-8.4 antigens, it was determined that although there are regions in common, these two chimeric antigens lacked the conserved epitope PEP2. This T. cruzi antigen has been previously identified and is a 22-amino acid sequence having the sequence GDKPSPFGQAAAGDKPSPFGQA (SEQ ID NO: 7). Houghton et al., J. Infect. Dis. 179:1226-34 (1999): As a result of this information, the present inventors determined that the addition of the amino acid fragment PEP2 into the IBMP 8.1 and / or IBMP 8.3 chimeric antigen could be used to greatly improve the sensitivity, specificity, and accuracy of immunoassays designed to test for T. cruzi antigens and thus be able to greatly enhance the capacity for diagnosing Chagas Disease in human or animal patients such as mammals, including domestic pets such as cats and dogs which are often affected by this diease. In one suitable embodiment of the present invention, the modified chimeric antigens IBMP 8.1 and / or IBMP 8.3 will be incorporated into a diagnostic immunoassay such as a lateral flow assay. Such an assay may be used to detect the presence or absence of antibodies against Trypanosoma cruzi and may comprise the modified chimeric antigens IBMP 8.1 and / or 8.3 that are modified to contain a PEP2 antigen inserted therein. The assay may also include suitable immunobinding detection reagents which provide a signal that indicates immunobinding when an antibody against Trypanosoma cruzi binds with said modified chimeric antigens. In addition to the modified IBMP 8.1 and / or 8.3 antigens as described above, the antigenic composition of the invention may also include unmodified IBMP 8.4 antigen, such as the one with the amino acid sequence of SEQ ID NO: 8 described herein. In either case, the modified chimeric antigen composition of the invention may be combined with immunobinding detection reagents that provide a signal that indicates immunobinding when an antibody against Trypanosoma cruzi binds with said chimeric antigen so as to form a suitable immunoassay in accordance with the invention. These assays are used by obtaining a sample of a bodily fluid or other biological matrix from a human or animal subject or patient that is undergoing testing to determine if antibodies to T. cruzi are present, and the sample will travel through the immunoassay to a detection region that includes the immunobinding reagents as set forth above which can generate a signal indicative of binding of the antigens in the immunoassay with antibodies from T. cruzi that are present in the sample. The present invention is advantageous because modifying the number of amino acid fragments in the IBMP 8.1 and IBMP 8.3 chimeric antigens to include PEP2 results in a great improve with regard to the sensitivity, specificity, and accuracy of an assay that includes the modified antigens of the invention. The improvement thus enhances the ability to accurately detect and diagnose Chagas disease in humans and pets. In addition, these modifications overcome the shortcomings of current commercially available testing including problems such as false negatives due to variation in antigen across multiple strain types in the world. The present invention also provides the ability to detect antigens at various levels associated with different phases of Chagas disease. In still further exemplary embodiments, a chimeric antigen for diagnosing a Chagas disease infection is provided wherein the chimeric antigen comprises a modified IBMP 8.1 antigen and an unmodified IBMP 8.3 antigen, wherein the modified IBMP 8.1 chimeric antigen contains at least one PEP2 antigen. In addition, a chimeric antigen for diagnosing a Chagas disease infection is provided wherein the chimeric antigen comprises a modified IBMP 8.3 antigen and an unmodified IBMP 8.1 antigen, wherein the modified IBMP 8.3 chimeric antigen contains at least one PEP2 antigen. As indicated below, in the antigenic compositions of the invention, this construct may also include an unmodified IBMP 8.4 antigen in combination with the modified IBMP 8.1 and 8.3 antigens as described herein. In one exemplary example of the invention, a lateral flow assay is provided that contains the modified chimeric antigen composition as identified above. In such an example, the antigenic composition comprises the IBMP-8.1 and / or IBMP-8.3 modified T. cruzi chimeric antigens will utilized on test strips, such as those made of a nitrocellulose membrane, and the antigens are dispensed in parallel with the assay reaction control onto the test strips as part of a lateral flow immunochromatography platform. In an exemplary test, the assay comprises a multimembrane strip sequentially arranged onto an adhesive card that contains a sample pad, a conjugate pad, the chimeric antigen composition, a control-impregnated nitrocellulose membrane, and a residual membrane or wick. The test strip of the assay of the invention may be placed inside a device such as a plastic cassette where the reaction takes place after a sample is obtained from a human or animal patient, combined with a buffer, and applied onto the test strip. In one suitable example, the device of the invention contains an opening for sample dispensing / running buffer at one portion of the test strip, and a reaction display window at the point wherein a signal reflective of immunobinding may appear. In one exemplary example, 0ne to five (1-5) microliters of the sample are dispensed on the opening at the dispensing side followed by the addition of 1-3 drops of running buffer to allow the sample liquid to flow through the length of the test strip. The mixture migrates by capillary action, eluting the conjugate to a test area where the antigens impregnated on the test strip are located. The overflow of components migrates to the opposite end of the strip where they are retained via a wick pad or other blotting agent. The results of the immunoassay testing may be obtained in a number of ways depending on the signal generated by the immunobinding reagents, and such signals may be visual so as to be easily observable by the clinician administering the test. In one suitable example, results may appear visually to the clinician after 5-10 minutes following dispensing of the sample at room temperature (avg.22°C) but may also be obtained in a variety of suitable ways, such as by acquiring a digital photographic image of the detection zone. In certain embodiments, positive results may be characterized by the presence of colorimetric signals, e.g., grey-green color bands in the test line containing the modified chimeric antigens IBMP 8.1 and / or 8.3, optimally with the IBMP-8.4 antigen). Another colorimetric signal may be provided as a control, such as a red control which ensures that the sample has migrated sufficiently through the test strip. In one suitable example, following testing, the red control line appearing alone will indicate a negative test, which the presence of the grey-green line in addition to the red control line will indicate a positive test result. Another exemplary embodiment of an assay in accordance with the present invention is shown in schematic drawing Figure 1. This figure shows the assay orientation on the test strip, and in this embodiment, a test strip has a sample pad wherein the sample is applied, and a filter pad is added along the test strip which may filter out undesirable elements in the sample. At a point in the middle of the test strip, there is a test line wherein the modified chimeric antigen of the invention is located, and this will contain the antigen in such a manner that antibodies to T. cruzi will bind with the modified chimeric antigen of the invention, and such binding will generate a signal that can be observed by visual or other suitable means. The test strip also contains a control line which will show that the sample has migrated sufficiently throughout the test strip including the test zone wherein the antigens are located. Finally, a wick pad can be included at the end of the test strip opposite to the sample pad which will prevent the fluid from going further. In the exemplary embodiment described above and shown in Figure 1, the control line is comprised of streptavidin-40 in connection with a suitable dye so that the fluid reaching the control line will provide a colorimetric signal indicating the test is valid. The modified chimeric antigen is coated onto the test strip so that it can bind with a T. cruzi antibody in the sample, and the binding of the T. cruzi is shown by detection reagents which in this case comprise an anti-species antibody that will bind to the T. cruzi antibody, and the anti-species antibody is connected with a marker or signal such as 150 nm gold nanoshell (GNS) which can provide a colorimetric signal when a T. cruzi antibody in the sample becomes bound to the modified chimeric antigen on the test strip. As indicated above, the antigenic composition of the present invention comprises a modified IBMP 8.1 antigen and / or a modified 8.3 antigen, said antigens being modified by the inclusion therein of one or more PEP2 antigens. In exemplary embodiments, the PEP2 antigens can be placed in any suitable location on either the IBMP 8.1 antigen or 8.3 antigen such as in any of the regions specified in the Tables above which set forth the various antigens constituting the chimeric antigen. These regions in IBMP chimeric antigen 8.1 include the trans-sialidase regions at amino acid ranges 747-774 and 1435-1449, respectfully, the 60S ribosomal protein L19 at 218- 238, and surface antigen 2 (CA-2) at aa 279-315. In IBMP chimeric antigen 8.3, these regions include the trans-sialidase region at amino acids 710-754, the flagellar repetitive antigen protein at amino acids 15-56, the 60S ribosomal protein L19 at amino acids 236- 284, and surface antigen 2 (CA-2) at amino acids 279-315. The PEP2 may be ideally inserted between any of these regions or any other suitable locations along chimeric antigens 8.1 and 8.3 so as to maximize the antigenic effect of all of the antigens in the IBMP chimeric antigens. In one exemplary embodiment, the modified chimeric antigen IBMP 8.1 includes a single PEP2 antigen embedded therein, but modifications wherein more than one PEP2 antigen are inserted are also possible. In one suitable embodiment, a modified IBMP 8.1 is provided which has two PEP2 antigens inserted therein and has the amino acid sequence indicated below as SEQ ID NO: 1, or may have one PEP2 antigen inserted therein as shown in SEQ ID NO.2: As indicated in Table 3 below, the IBMP 8.1 chimeric antigens are shown with the 6X His tag sequence as indicated by the MGSSHHHHHH sequence at the beginning of each sequence, and the sequence also includes a stop codon at the end to indicate termination of the sequence, designated by the periods. This initiation sequence and stop codon are shown in all sequences below. Table 3: Exemplary sequences for modified 8.1 chimeric antigens MGSSHHHHHHGSEEGSRGDSSMPASASEEGSRGDSSMPAKAAIAPAKAAAAP In another exemplary embodiment of the invention, one or more PEP2 antigens are inserted in suitable locations in the modified chimeric antigen IBMP 8.3 of the invention. As indicated above, the PEP2 antigen is inserted into the IBMP 8.3 chimeric antigen in any suitable location that will maximize the immunogenic effect of the antigens when used in diagnostic tests to determine the presence of antibodies to T. cruzi in human or animal subjects. Exemplary embodiments of the modified chimeric 8.3 antigen are shown below wherein one or more PEP2 antigens are inserted therein in multiple locations. Table 4: Exemplary sequences for modified 8.3 chimeric antigens In additional embodiments he present invention relates to a modified chimeric IBMP antigen for use in detecting the parasite Trypanosoma cruzi in human and animal subjects with greater accuracy and fewer false positive tests. In this modified chimeric IBMP antigen, the antigens IBMP 8.1 and 8.3 are modified for use in detecting the presence of Trypanosoma cruzi in order to diagnose Chagas disease in a human or animal patient, and the modification may be obtained by inserting the PEP2 peptide and optionally other T. cruzi antigens into the IBMP 8.1 and / or 8.3 antigens, and using the modified antibodies to detect the presence of antibodies to T. cruzi in human and animal patients. An IBMP 8.4 antigen is used along with the modified 8.1 and 8.3 antigens. The modified chimeric antigens including the modified IBMP 8.1 and 8.3 antigens along with IBMP 8.4 may be used in a lateral flow assay or other suitable assays for the detection of T. cruzi and the diagnosis in a human or animal patient of a Chagas disease infection. Test kits employing these chimeric antigens are also provided as described further below. In one exemplary aspect of the present invention a chimeric antigen is provided which comprises a modified IBMP 8.1 antigen and / or a modified IBMP 8.3 antigen, wherein either of both of the modified IBMP 8.1 and / or 8.3 antigens contain at least one PEP2 antigen inserted therein. The PEP2 may be inserted in the modified chimeric IBMP 8.1 and / or 8.3 antigens in any suitable location where it will supplement the antigenic effect of the IBMP protein and will provide a more accurate and sensitive test for the presence of T. cruzi antigens in human and animal patients. Insertions of PEP2 can be at a variety of locations, such as at the start or end of the many of the specific regions of the IBMP 8.1 and 8.3 antigens as described herein. As indicated above, specific examples are provided wherein the modified IBMP 8.1 antigen has amino acid sequence SEQ ID NOS: 1 or 2, and other suitable examples are provided wherein the modified IBMP 8.3 antigen of the invention has an amino acid sequence that is selected from the group consisting of SEQ ID NOS 3-6. Still other suitable forms of PEP2 insertion within the present invention are possible as would be understood by those of ordinary skill in the art. In these embodiments, the modified 8.1 and 8.3 IBMP antigens may contain one PEP2 antigen or a plurality of PEP2 antigens as needed to maximize the usefulness of these antigens in forming an efficient and highly accurate testing assay for T. cruzi antibodies and infections of Chagas diease in human and animal patients. In another exemplary embodiment, a chimeric antigen for diagnosing a Chagas disease infection is provided wherein the chimeric antigen comprises a modified IBMP 8.1 antigen and a modified IBMP 8.3 antigen, wherein the modified IBMP 8.1 and 8.3 antigens contain at least one PEP2 antigen. As indicated below, in the antigenic composition of the invention, this construct may also include an unmodified IBMP 8.4 antigen in combination with the modified IBMP 8.1 and 8.3 antigens as described herein. In accordance with the present invention, the modified chimeric antigen of the invention for use in diagnosing a Chagas disease infection may be provided which comprises the modified IBMP 8.1 and 8.3 antigens described above which include at least one PEP2 antigen, but also include a second antigen from T. cruzi. As indicated above, there are a number of immunogenic antigens in T. cruzi, and one or more of these may be inserted into the modified 8.1 and 8.3 antigens of the present invention. In certain embodiments, the additional T. cruzi antigens may be selected from the group consisting of 1F8, rTc24 (PGR24-His), TcF, SAPA, TSSA, SAPA / TSSA, SAPA / TSSA, FRA, B13, MACH (PEP2, TcD, TcE, SAPA), TcD, and TcE antigens. In certain embodiments, the second antigen has a sequence selected from the group consisting of SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:14, and these sequences are shown in Table 5 below. Exemplary sequences for the second antigen to be included in the modified 8.1 and / or 8.3 chimeric antigens are as follows: Table 5: Exemplary sequences for the second antigen included in the modified 8.1 and / or 8.3 chimeric antigens In other embodiments, the chimeric antigen may comprise modified IBMP 8.1 and 8.3 antigens and an unmodified IBMP 8.4 chimeric antigen. In certain embodiments, the unmodified IBMP chimeric antigen may have the following sequence: As also indicated above, the chimeric antigen of the invention may comprise modified IBMP 8.1 and / or a modified IBMP 8.3 antigen, and in certain exemplary embodiments, the chimeric antigen may comprise a modified 8.1 antigen combined with an unmodified IBMP 8.3 antigen, and vice versa wherein a modified IBMP 8.3 antigen is combined with an unmodified IBMP 8.1 antigen. In both cases, these antigens may also be combined with an unmodified IBMP 8.4 chimeric antigen as described herein. In certain embodiments, the unmodified IBMP 8.1 chimeric antigen may have the following sequence: In certain embodiments, the unmodified IBMP 8.3 chimeric antigen may have the following sequence: In certain exemplary embodiments, the modified IBMP 8.1 and / or 8.3 antigens and unmodified IBMP 8.4 antigen may be used as described above, or the modified IBMP 8.1 and / or 8.3 antigens may further contain a second antigen in addition to the one or more PEP2 antigens as set forth herein. In certain embodiments, the second antigen may be selected from the group consisting of 1F8, rTc24 (PGR24-His), TcF, SAPA, TSSA, SAPA / TSSA, SAPA / TSSA, FRA, B13, MACH (PEP2, TcD, TcE, SAPA), TcD, and TcE antigens. As indicated above, in exemplary embodiments, the modified IBMP 8.1 antigen of the invention may have the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO.2, and the modified IBMP 8.3 antigens of the invention may have an amino acid selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6. In certain embodiments the PEP2 antigen may have the amino acid sequence of SEQ ID NO: 7. In accordance with the invention a qualitative, membrane-based immunoassay is provided for detecting Trypanosoma cruzi, in canine serum and whole-blood matrices by applying the modified chimeric antigens as described herein which include an inserted PEP2 region to increase sensitivity and specificity of the assay. As indicated herein, there are many forms of immunoassay that may be utilized in accordance with the invention, and exemplary modalities for carrying out the present diagnostic method include a lateral flow immunoassay, a multiple antigen blot assay; and an enzyme- linked immunosorbent assay (ELISA). Still further, the present invention may also use a dot immunobinding assay which comprises lining up the antigen repertoire on a nitrocellulose membrane reformatted into a dipstick immunoassay format. As indicated herein, a method of determining the presence of antibodies to T. cruzi in a human or animal patient id provided in accordance with the invention wherein the chimeric antigen as described herein is used in an immunoassay of a sample from the human or animal subject, and the presence of antibodies to t. cruzi in the sample is determined by the identification of binding when the sample is contacted with the chimeric antigen of the invention. As indicated herein, determination of the presence of antibodies that bind to the described chimeric antigens can be performed using any suitable approach, including but not limited to any type of enzyme-linked immunosorbent assay (ELISA) assay, including but not limited to a direct ELISA, a sandwich ELISA, a competitive ELISA, and a reverse ELISA. In certain embodiments, the chimeric antigen described herein can be incorporated into an immunodiagnostic device, such as a microfluidic device, a lateral flow device, and the like. In non-limiting embodiments, the disclosure provides for a device configured to generate a signal that is based on antibodies bound to the chimeric antigens of the invention. In additional embodiments, the signal is optically accessible so that at least some antibodies, if present in the biological sample, are bound to the chimeric antigen as described herein. In certain embodiments, the antibodies are bound to the chimeric antigen, and the assay further comprises detectably labeled antibodies bound to the antibodies that are bound to the chimeric antigens. Thus, in one approach, the disclosure includes determining a signal from the detectably labeled antibodies. The detection antibodies or other detection agent can be labeled using any suitably detectable label. In certain embodiments, the detectable labels produce a signal that comprises UV light (<380 nm), visible light (380-740nm) or far red light (>740 nm). In certain embodiments, the detectable signal comprises a fluorescent signal, and relative light units (RLUs) may be used to determine ratios of signals from different antibodies. In addition, a cell-based assay as described herein can be used in the methods of the disclosure. In certain embodiments, a suitable laser may also be used. Further, in assays in accordance with the invention, any suitable imager located proximal to analyzed samples as well as free-space optics may be used to detect a signal from the assay using any suitable signal detection device such as a CCD camera placed in proximity to the location where a detectable signal is generated. In additional embodiments, a microfluidic device is provided for use in sample analysis that may comprise, among other features, an optical waveguide to transmit a signal to any suitable measuring device such that optical accessibility to sample is not necessarily required to detect the signal. In embodiments, lens-less optics, and / or a cell phone based imaging approach is used. In these embodiments, one or more segments of an assay device on which the described antibody analysis is performed can be connected to or in communication with a digital processor and / or a computer running software to interpret the presence, absence, amount, or a ratio of antibodies that bind to the chimeric antigens as described herein. The processor may run software and / or implement an algorithm to interpret an optically detectable signal, and generate a machine and / or user readable output. In one exemplary embodiment, an assay device used to perform the antibody analysis can be integrated or otherwise inserted into an adapter that comprises a detection device, such as a camera, or a microscope, including but not limited to a fluorescent microscope. In other exemplary embodiments, a computer readable storage medium can be a component of an assay device in accordance with the present disclosure, and can be used during or subsequent to performing any assay or one or more steps of any assay described herein. In certain embodiments the computer storage medium is a non-transitory medium, and thus can exclude signals, carrier waves, and other transitory signals. In still further exemplary embodiments, the modified chimeric antigens and / or a combination of modified and unmodified chimeric antigens in accordance with the present disclosure are used in a device referred to in the art as a "BioCD" device, and thus detectable labels may not be required. In these exemplary embodiments, the BioCD is a differential phase-contrast BioCD biosensor, such as that described in "Differential phase-contrast BioCD biosensor," Appl Opt.46:6196-6209 (2007), from which the entire description is incorporated by reference. In certain embodiments, the presently described chimeric antigens are used in a device and / or method as described in U.S. patents 10,100,092, 7,910,356, 7,787,126, and 7,663,092, said patents being incorporated by reference as if set forth in their entirety herein, including the disclosures of devices for use in immunoassays, and methods of using the devices, in accordance with the present invention. In other exemplary embodiments, an assay result may be obtained by using a method and / or device and / or system that can be compared to any suitable reference, examples of which may include control sample(s), a standardized curve(s), and / or experimentally designed controls such as a known input value. In other embodiments, the control may use a different antigen / antibody configuration than antigen / antibody configurations from which the test result using a biological sample is obtained. In one example, the antigen is attached to a substrate in a device, and the antigen may be immobilized or otherwise in contact with an antibody that is attached to a substrate. The antigen may be detectably labeled or used in combination with a detection antibody that is detectably labeled. In certain embodiments, the control can be a different isotype or species of origin for a capture or detection antibody, relative to the isotype or species of origin for a capture or detection antibody that is used to analyze a biological sample. In certain embodiments, the modified and unmodified antigens of the invention can be modified using any suitable approach well known in the art, including but not limited to the addition of one or more purification tags, such as a His-tag. In an exemplary embodiment, a His-tag is a linear sequence of n histidine residues where n is typically 6-10. His-tags achieve purification by binding specifically to nickel or cobalt ions, which may be for example, attached to a substrate, such as any suitable beads. The His-tag, or any other suitable purification tag, may be placed at the N-terminus, or at the C-terminus of the protein or peptide. In other embodiments, a FLAG-tag, or FLAG octapeptide, or FLAG epitope, may be included, and suitable FLAG sequences are known in the art. In certain embodiments, a Small ubiquitin-related modifier (SUMO) tag, such as a His-SUMO tag can also be used. In other exemplary embodiments of the invention, one or more of the chimeric antigens of the disclosure may also comprise a linker as would also be well known in the art. The term "linker" generally refers to a chemical moiety that connects a segment of the chimeric antigen to another material, and suitable linkers can include amino acids and other types of linking groups. In general, amino acid linkers may be principally comprised of relatively small, neutral amino acids, such as Glycine, Serine, and Alanine, and can include multiple copies of a sequence enriched in Glycine and Serine. In certain embodiments, the linker is provided as a means to connect the chimeric antigen to a substrate. As such, the linker may be attached to a binding partner that connects the antigen to a substrate. Non-limiting examples of binding partners include streptavidin and biotin. In certain embodiments, the chimeric antigens of the invention may be attached to an array that includes substrates to which the antigens can bind. The attachment may or may not be via a linker. In various embodiments, the present chimeric antigens can be reversibly or irreversibly attached to a substrate, such as by being covalently, ionically, or physically bound to a solid- phase substrate using methods such as covalent bonding via an amide or ester linkage, ionic attraction, or by adsorption. As indicated above, non-limiting examples of such binding may comprise biotin and streptavidin tags. The substrate can be any suitable substrate onto which one or more of the chimeric antigens described herein can be attached. Examples include substrates typically used in immunodetection assays, lateral flow devices, bead-based assays, nanoparticles such as gold nanoparticles, microfluidic devices, etc. Thus, a solid substrate can be a porous solid substrate that allows the flow of liquid through the substrate. The liquid can flow through the porous substrate via any suitable means, such as by capillary action, microfluidics, etc. The substrate can also be a non-porous solid substrate, such as beads formed from glass or other non-porous materials, such as plastic. In certain embodiments, the substrate and the chimeric antigens may be functionalized to facilitate their attachment. The substrate may be blocked prior to attaching the chimeric antigens to reduce artifacts, and some assays may also be performed in solution. In certain embodiments, the chimeric antigens of the invention are present in vitro, such as in an in vitro assay and are arranged so as to allow the antigens to be placed in contact with a biological sample obtained from a human or animal subject, such as any mammal. Representative subjects for the detection methods of the present invention may include canines and felines, as well as other mammals that may be kept as pets. In certain embodiments, the biological sample is obtained from an animal who has been exposed or is suspected of having been exposed, or was at risk of exposure, to Chagas disease. In certain embodiments a result based on a determination of the presence, absence, amount, type, ratio, or a combination thereof for antibodies analyzed using an approach and / or a device of this disclosure is obtained and is fixed in a tangible medium of expression, such as a digital file, and / or is saved on a portable memory device, or on a hard drive, or is communicated to a web- based or cloud-based storage system. The determination can be communicated to, for example, a veterinary health care provider for the purpose of making a diagnosis, and / or recommending or not recommending any particular medical intervention. The chimeric antigens of the invention may also be used in assays that are included in test kits. Such test kits can include, for example, one or more of the chimeric antigens as described herein along with detection materials for the identification of antigen-antibody binding as described herein, and these materials may be provided in suitable packaging identifying the tests that will be conducted. The kit may be provides with suitable reagents to identify T. cruzi antibodies when bound to the chimeric antigens, and the kit may include means for sample collection. The kit can also be provided as a component of a cartridge or similar component, or for example a multi-well plate. Such components may be provided pre-loaded with any combination of reagents required to perform the described analysis, including a suitable substrate and certain reagents as a lyophilized form for reconstitution in, for example, a suitable immunodiagnostic buffer. In various embodiments, the kits may also include printed material, such as the label or the instructions regarding carrying out the assays using the chimeric antigens of this disclosure. The printed material can be part of the packaging or label, and may further provide information showing or explaining the contents of the kit, or this information may be provided on packaging that includes the kit. The present invention thus relates to a modified chimeric IBMP antigen for use in detecting the parasite Trypanosoma cruzi in human and animal subjects with greater accuracy and fewer false positive tests. In this modified chimeric IBMP antigen, the antigens IBMP 8.1 and 8.3 are modified for use in detecting the presence of Trypanosoma cruzi in order to diagnose Chagas disease in a human or animal patient, and the modification may be obtained by inserting the PEP2 peptide and optionally other T. cruzi antigens into the IBMP 8.1 and / or 8.3 antigens, and using the modified antibodies to detect the presence of antibodies to T. cruzi in human and animal patients. An IBMP 8.4 antigen is used along with the modified 8.1 and 8.3 antigens. The modified chimeric antigens including the modified IBMP 8.1 and 8.3 antigens along with IBMP 8.4 may be used in a lateral flow assay or other suitable assays for the detection of T. cruzi and the diagnosis in a human or animal patient of a Chagas disease infection. Test kits employing these chimeric antigens are also provided as described further below. In one exemplary aspect of the present invention a chimeric antigen is provided which comprises a modified IBMP 8.1 antigen and / or a modified IBMP 8.3 antigen, wherein either of both of the modified IBMP 8.1 and / or 8.3 antigens contain at least one PEP2 antigen inserted therein. The PEP2 may be inserted in the modified chimeric IBMP 8.1 and / or 8.3 antigens in any suitable location where it will supplement the antigenic effect of the IBMP protein and will provide a more accurate and sensitive test for the presence of T. cruzi antigens in human and animal patients. Insertions of PEP2 can be at a variety of locations, such as in many of the specific regions of the IBMP 8.1 and 8.3 antigens as described herein. Specific examples are provided below wherein the modified IBMP 8.1 antigen has amino acid sequence SEQ ID NOS: 1 or 2, and other suitable examples are provided wherein the modified IBMP 8.3 antigen of the invention has an amino acid sequence that is selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6. Still other suitable forms of PEP2 insertion within the present invention are possible as would be understood by those of ordinary skill in the art. In these embodiments, the modified 8.1 and 8.3 IBMP antigens may contain one PEP2 antigen or a plurality of PEP2 antigens as needed to maximize the usefulness of these antigens in forming an efficient and highly accurate testing assay for T. cruzi antibodies and infections of Chagas diease in human and animal patients. In another exemplary embodiment, a chimeric antigen for diagnosing a Chagas disease infection is provided wherein the chimeric antigen comprises a modified IBMP 8.1 antigen and a modified IBMP 8.3 antigen, wherein the modified IBMP 8.1 and 8.3 antigens contain at least one PEP2 antigen. As indicated below, in the antigenic composition of the invention, this construct may also include an unmodified IBMP 8.4 antigen in combination with the modified IBMP 8.1 and 8.3 antigens as described herein. In an additional exemplary embodiment of the present invention, there is provided a chimeric antigen for use in diagnosing a Chagas disease infection that comprises a modified IBMP 8.1 antigen and / or a modified IBMP 8.3 antigen, and the modified 8.1 and / or 8.3 antigens include at least one PEP2 antigen as set forth above and may also be combined with an unmodified IBMP 8.4 antigen. In certain embodiments, the IBMP 8.4 antigen will have the amino acid sequence of SEQ ID NO: 8. In another exemplary embodiment, the chimeric antigen of the invention for use in diagnosing a Chagas disease infection may be provided which comprises a modified IBMP 8.1 antigen and a modified IBMP 8.3 antigen, wherein the modified IBMP 8.1 and 8.3 antigens contain at least one PEP2 antigen and a second antigen from T. cruzi, such as an antigen selected from the group consisting of 1F8, rTc24 (PGR24- His), TcF, SAPA, TSSA, SAPA / TSSA, SAPA / TSSA, FRA, B13, MACH (PEP2, TcD, TcE, SAPA), TcD, and TcE antigens. In certain embodiments, the second antigen has a sequence selected from the group consisting of SEQ ID NOS: 11-14. In other embodiments, the chimeric antigen may comprise modified IBMP 8.1 and 8.3 antigens and an unmodified IBMP 8.4 antigen, wherein the modified IBMP 8.1 and 8.3 antigens contain at least one PEP2 antigen and a second antigen selected from the group consisting of 1F8, rTc24 (PGR24-His), TcF, SAPA, TSSA, SAPA / TSSA, SAPA / TSSA, FRA, B13, MACH (PEP2, TcD, TcE, SAPA), TcD, and TcE antigens. As indicated above, the modified IBMP 8.1 antigen may have the amino acid sequence of SEQ ID NOS: 1 or 2, and the modified IBMP 8.3 antigen may have an amino acid sequence such as SEQ ID NOS: 3-6. In certain embodiments the PEP2 antigen may have the amino acid sequence of SEQ ID NO: 7. In another exemplary embodiment of the present invention, an immunoassay for detecting antibodies against Trypanosoma cruzi is provided which comprises the chimeric antigen as described above which includes a modified 8.1 and / or 8.3 antigen containing a PEP2 antigen inserted therein along with immunobinding detection reagents which provide a signal that indicates immunobinding when an antibody against Trypanosoma cruzi binds with said chimeric antigen. Such an immunoassay may be selected from the group consisting of lateral flow immunoassay, multiple antigen blot assay, direct or indirect Enzyme-linked immunosorbent assay (ELISA), enzymatic immunoassay, sandwich assay, electrochemilumescence assay, dipstick immunoassay, and radioisotope assay. In an alternative embodiment, the chimeric antigen of the immunoassay may be constructed to include a modified 8.1 and / or 8.3 antigen containing a PEP2 antigen inserted therein along with an unmodified IBMP 8.4 antigen. This chimeric antigen can then be combined with immunobinding detection reagents which provide a signal that indicates immunobinding when an antibody against Trypanosoma cruzi binds with said chimeric antigen so as to form a suitable immunoassay in accordance with the invention. The immunoassay may be a lateral flow immunoassay or any of a number of conventional immunoassays well known in the art. In use, the immunoassay is used to receive a sample of a bodily fluid or other biological matrix from a human or animal subject or patient that is undergoing to determine if antibodies to T. cruzi are present, and the sample will travel through the immunoassay to a detection region that includes the immunobinding reagents as set forth above which can generate a signal indicative of binding of the antigens in the immunoassay with antibodies from T. cruzi that are present in the sample. In other suitable embodiments, the immunobinding detection reagents of the immunoassay of the invention may comprise those reagents which generate a signal that indicates immunobinding when an antibody against Trypanosoma cruzi binds with said chimeric antigen. The signal used in the present immunoassay can be any appropriate materials that will provide a visual or other identification indicating that immunobinding has taken place and that the antibodies to T. cruzi are present in the sample from the subject. The signal itself can be any conventional signal used in diagnostic assays including a signal selected from the group consisting of a colorimetric signal, a fluorescent signal, a chemiluminescent signal, a radioactive signal, and a visual signal. In one exemplary embodiment, the present immunoassay will be a lateral flow immunoassay capable of detecting the presence or absence of antibodies against Trypanosoma cruzi, and this lateral flow assay can include the modified chimeric antigens as set forth above, with or without the unmodified chimeric antigens also described herein. In certain embodiments, the modified chimeric antigen used in the lateral flow immunoassay of the invention may be an IBMP chimeric antigen 8.1 and / or a modified IBMP chimeric antigen 8.3 that is modified by adding at least one PEP2 antigen. In alternate embodiments, the modified chimeric antigen in this lateral flow immunoassay may be an IBMP chimeric antigen 8.1 and / or a modified IBMP chimeric antigen 8.3 that each include at least one PEP2 antigen inserted therein combined with an unmodified IBMP 8.4 chimeric antigen as is described further herein. In still further embodiments, in addition to the PEP2 antigen, the modified chimeric antigens of the invention may also include a second T. cruzi antigen, including those antigens selected from the group consisting of consisting of 1F8, rTc24 (PGR24-His), TcF, SAPA, TSSA, SAPA / TSSA, SAPA / TSSA, FRA, B13, MACH (PEP2, TcD, TcE, SAPA), TcD, and TcE antigens. In another exemplary embodiment of the invention, an immunoassay method is provided for detecting the presence or absence of antibodies against Trypanosoma cruzi in a human or animal subject wherein the immunoassay method comprises providing the modified chimeric antigen as described above which contains at least one PEP2 antigen inserted into a modified IBMP 8.1 chimeric antigen and / or a modified IBMP 8.3 chimeric antigen. The modified chimeric antigen of the invention will be used to determine whether a human or animal patient tests positive for the presence of T. cruzi antibodies, so a sample from the human or animal patient is obtained for use of the method. A suitable sample is obtain from a bodily fluid or other biological matrix from the patient, and this sample is contacted with the modified chimeric antigen as described above. In an exemplary method, the detection of T. cruzi antibodies is carried out by contacting said sample with said modified chimeric antigen of the invention; and then determining the presence or absence of antibodies against Trypanosoma cruzi by detecting immunobinding of said chimeric antigen to Trypanosoma cruzi im sa1d sample. In an alternate embodiment, the modified 8.1 and 8.3 antigens can be combined with an unmodified IBMP 8.4 antigen in the chimeric antigenic composition used in the immunoassay method of the present invention. This immunoassay method may be carried out in any suitable form, such as an immunoassay selected from the group consisting of lateral flow immunoassay, multiple antigen blot assay, direct or indirect Enzyme-linked immunosorbent assay (ELISA), enzymatic immunoassay, sandwich assay, electrochemilumescence assay, dipstick immunoassay, and radioisotope assay. In another exemplary embodiment, the modified chimeric antigens IBMP 8.1 and 8.3 antigens can be used in a method of diagnosing a Chagas disease infection in a human or animal subject. In such a method, there is provided the modified chimeric antigens IBMP 8.1 and 8.3 antigens as described above wherein each of said chimeric antigens contain at least one PEP2 antigen embedded therein. In this exemplary method, a sample is obtained from a human or animal patient, such as a bodily fluid or other biological matrix, and this sample is placed in contact with the modified chimeric antigen of the invention, such as on a test strip in an immunoassay; such as a lateral flow immunoassay. By virtue of contacting the sample with the modified chimeric antigen of the invention, the presence or absence of antibodies against Trypanosoma cruzi is determined by detecting immunobinding of the chimeric antigen to Trypanosoma cruzi antibodies in the sample, and the presence of such antibodies are indicative that the human or animal patient is infected with Chagas disease. As indicated above, such a method can be conducted as a lateral flow immunoassay, but numerous other forms of immunoassays may be employed, including multiple antigen blot assays, direct or indirect Enzyme-linked immunosorbent assays (ELISA), enzymatic immunoassays, sandwich assays, electrochemilumescence assays, dipstick immunoassays, and radioisotope assays. An alternative immunoassay method of detecting or diagnosing a Chagas disease infection in a human or animal subject is also provided wherein the modified chimeric antigens used include a modified IBMP 8.1 antigen and a modified 8.3 antigen, both of which will include PEP2 antigens implanted therein, and also will include an unmodified IBMP 8.4 antigen. As in the method described above, the modified chimeric antigen is provided, such as on a test strip, and a sample of bodily fluid or other biological matrix from a human or animal subject is obtained and contacted with this modified chimeric antigen. Any resulting immunobinding to the antigen reflects that there are T. cruzi antibodies in the sample and that the human or animal being testing is infected with Chagas disease. The immunobinding of said chimeric antigen to Trypanosoma cruzi im sa1d sample can be determined by any suitable reagents that can emit an observable In another aspect of the present invention, a test strip is provided that can be utilized for qualitatively determining the present or absence of antibodies against Trypanosoma cruzi which will be indicative of a Chagas disease infection. Such a test strip may be made of a nitrocellulose membrane or other materials which will allow flow through the test strip, such as by capillary action, so that a sample at one end of the strip will migrate through the strip wherein the sample can be contacted by the modified chimeric antigens of the invention, and so that a detection zone is present on the test strip wherein a signal reflecting that immunobinding has occurred between the modified chimeric antigens on the test strip and the antibodies in the sample. As indicated above, the antigen composition used on said test strip may comprise a modified IBMP 8.1 antigen and a modified IBMP 8.3 antigen which both include at least one PEP2 antigen inserted therein. These two antigens may also be combined with an unmodified IBMP 8.4 chimeric antigen in the antigenic composition used in the present invention. Such test strips may be used alone or in cassettes or other devices wherein multiple test strips may be used at the same time. In another exemplary embodiment of the present invention, an immunoassay device is provided for conducting an immunoassay of antibodies against T. cruzi in a human or animal subject. The device comprises a test strip that is pre-coated with the modified chimeric antigen of the invention that comprises modified chimeric IBMP antigens 8.1 and 8.3, each having one or more PEP2 antigens inserted therein. In certain embodiments, the antigenic mix in the test strip of the device may also include an IBMP chimeric antigen 8.4. This immunoassay device of the invention also includes a detection reagent that detects binding between said modified chimeric antigens on the test strip and an antibody against T. cruzi located in a bodily fluid or other biological matrix sample obtained from human or animal subject. The test strip may be comprised of a nitrocellulose membrane, or other suitable materials well known in the field that are used that undergo capillary or wicking action so that when a fluid is introduced at one end of the test strip, that fluid will laterally flow up the test strip so that any antibodies in the sample can combined with the pre-coated modified chimeric antigen as described herein. In one embodiment, the detection reagents generate a signal that indicates that binding of antibodies in the sample and the antigens on the test strip has been detected. Such a signal may be any suitable signal that can be observed either visually or in another form, and such signals can include a colorimetric signal, a fluorescent signal, a chemiluminescent signal, a radioactive signal, and a visual signal. In further embodiments of the present invention, a test kit for qualitatively detecting the presence or absence of antibodies against Trypanosoma cruzi in a sample of bodily fluid or other biological matrix from a human or animal is provided which comprises a modified chimeric antigen as described herein that comprises modified chimeric IBMP antigens 8.1 and 8.3 that have one or more PEP2 antigens inserted therein. In additional embodiments, the chimeric IBMP antigen 8.4 may also be used. In one embodiment, in addition to the modified chimeric antigen as described above, the test kit will also a test strip wherein the antigens can be located and immunobinding detection reagents that can be added to the test strip so as to provide a signal indicative of immunobinding of said chimeric antigen when the sample contains antibodies against Trypanosoma cruzi. In certain embodiments, the test strip will have a particular detection zone included therein wherein the signal indicative of immunobinding of said chimeric antigen on the test strip and Trypanosoma cruzi antibodies in the sample can be observed. The kit may also include devices such as a swab which collect the sample from a patient to be tested, and the sample can be a bodily fluid or other biological matrix from the patient. Suitable samples may be a bodily fluid, serum, whole blood, saliva, and / or other biological matrices. In the operation of the test kit, a sample is obtained from a human or animal patient being tested, such as by a cotton swab or other suitable device, and the sample may be placed in a buffer solution that may also be included in the test kit. Once the sample is obtained and placed into the buffer, solution a certain amount of the solution is then applied to the test strip so that the fluid will migrate from the application point through the test strip so that it can mix with the modified chimeric antigens in the test strip, and then reach a detection zone wherein a signal is generated (or not generated) that reflects presence or absence of T. cruzi antibodies in the sample obtained from the patient. Still further, the invention provides an immunoassay system for qualitatively detecting the presence or absence of antibodies against Trypanosoma cruzi in a human or animal subject that comprises the modified chimeric antigens 8.1 and 8.3 above, with or without an unmodified 8.4 IBMP antigen. These antigens may be located on a test strip to which is applied a sample of bodily fluid or other biological matrix from the human or animal subject that can be applied to said test strip. The system also includes an immunobinding detection reagent that will normally be located on said test strip and which provide a signal that indicates immunobinding of the antigens when the sample contains antibodies against Trypanosoma cruzi, and there is a detection zone on said test strip wherein the signal indicative of immunobinding between the antigens on the test strip and antibodies against Trypanosoma cruzi can be observed. The signal generated by virtue of the immunobinding may be selected from the group consisting of a colorimetric signal, a fluorescent signal, a chemiluminescent signal, a radioactive signal, and a visual signal. The test strip may be made of a nitrocellulose membrane but can also be any suitable material which undergoes capillary action so that a fluid sample can migrate laterally through the test strip and that antibodies in the sample may bind with the antigens on the test strip. The antigens, compositions, methods, systems, test strips, kits, and other aspects of the present invention using the modified chimeric antigen as described herein for the qualitative determination of the presence of the T. cruzi parasite that causes Chagas disease in humans and animals are further described herein. EXAMPLES: The invention will be further described by the following non-limiting examples. EXAMPLE 1 In one suitable embodiment of the present invention, the modified chimeric antigens IBMP 8.1 and / or IBMP 8.3 will be incorporated into a diagnostic immunoassay such as a lateral flow assay. Such an assay may be used to detect the presence or absence of antibodies against Trypanosoma cruzi and may comprise the modified chimeric antigens IBMP 8.1 and / or 8.3 that are modified to contain a PEP2 antigen inserted therein. The assay may also include suitable immunobinding detection reagents which provide a signal that indicates immunobinding when an antibody against Trypanosoma cruzi binds with said modified chimeric antigens. In addition to the modified IBMP 8.1 and / or 8.3 antigens as described above, the antigenic composition of the invention may also include unmodified IBMP 8.4 antigen, such as the one with the amino acid sequence of SEQ ID NO: 8 described herein. In either case, the modified chimeric antigen composition of the invention may be combined with immunobinding detection reagents that provide a signal that indicates immunobinding when an antibody against Trypanosoma cruzi binds with said chimeric antigen so as to form a suitable immunoassay in accordance with the invention. These assays are used by obtaining a sample of a bodily fluid or other biological matrix from a human or animal subject or patient that is undergoing testing to determine if antibodies to T. cruzi are present, and the sample will travel through the immunoassay to a detection region that includes the immunobinding reagents as set forth above which can generate a signal indicative of binding of the antigens in the immunoassay with antibodies from T. cruzi that are present in the sample. In one exemplary example of the invention, a lateral flow assay is provided as shown in Fig.1 that contains the modified chimeric antigen composition as identified above. In such an example, the antigenic composition comprises the IBMP-8.1 and / or IBMP-8.3 modified T. cruzi chimeric antigens will utilized on test strips, such as those made of a nitrocellulose membrane, and the antigens are dispensed in parallel with the assay reaction control onto the test strips as part of a lateral flow immunochromatography platform. In an exemplary test, the assay comprises a multimembrane strip sequentially arranged onto an adhesive card that contains a sample pad, a conjugate pad, the chimeric antigen composition, a control-impregnated nitrocellulose membrane, and a residual membrane or wick. The test strip of the assay of the invention may be placed inside a device such as a plastic cassette where the reaction takes place after a sample is obtained from a human or animal patient, combined with a buffer, and applied onto the test strip. In one suitable example, the device of the invention contains an opening for sample dispensing / running buffer at one portion of the test strip, and a reaction display window at the point wherein a signal reflective of immunobinding may appear. In one exemplary example, one to five (1-5) microliters of the sample are dispensed on the opening at the dispensing side followed by the addition of 1-3 drops of running buffer to allow the sample liquid to flow through the length of the test strip. The mixture migrates by capillary action, eluting the conjugate to a test area where the antigens impregnated on the test strip are located. The overflow of components migrates to the opposite end of the strip where they are retained via a wick pad or other blotting agent as shown in Fig. 1. The results of the immunoassay testing may be obtained in a number of ways depending on the signal generated by the immunobinding reagents, and such signals may be visual so as to be easily observable by the clinician administering the test. In one suitable example, results may appear visually to the clinician after 5-10 minutes following dispensing of the sample at room temperature (avg.22°C) but may also be obtained in a variety of suitable ways, such as by acquiring a digital photographic image of the detection zone. In certain embodiments, positive results may be characterized by the presence of colorimetric signal, e.g., grey-green color bands in the test line that contains the chimeric antigens identified above (e.g., the modified IBMP 8.1 and / or 8.3 antigens, optimally with the IBMP-8.4 antigen). Another colorimetric signal may be provided as a control, such as a red control which ensures that the sample has migrated sufficiently through the test strip. In one suitable example, following testing, the red control line appearing alone will indicate a negative test, which the presence of the grey-green line in addition to the red control line will indicate a positive test result. EXAMPLE 2 In accordance with the present invention, modified chimeric antigens IBMP 8.1 and / or IBMP 8.3 are prepared wherein one or more PEP2 antigens are inserted in suitable locations on both the IBMP 8.1 and 8.3 antigens that will improve the accuracy and sensitivity of immunoassay testing to detect the presence or absence of antibodies against Trypanosoma cruzi. In certain specific embodiments, there is one PEP2 antigen inserted into the chimeric 8.1 and / or 8.3 antigen, and in other embodiments, there are two or more PEP2 antigens. For example, with regard to the modified chimeric antigen, in certain embodiments, the modified 8.1 antigen of the invention may have the following sequence reflecting the insertion of two PEP2 antigens into the chimeric antigen: A.. (SEQ ID NO: 1) In another exemplary embodiment, the 8.1 antigen may have the following sequence reflecting the insertion of one PEP2 antigen into the chimeric antigen: In both of these cases, the modified IBMP 8.1 antigen may be combined with a modified IBMP 8.3 antigen as described herein, optionally along with an unmodified chimeric IBMP 8.4 antigen, and the modified chimeric antigen in accordance with the invention can be used in improved diagnostic methods and immunoassays used for the determination of the presence of T. cruzi antibodies in a human or animal subject. EXAMPLE 3 In accordance with the present invention, modified chimeric antigens IBMP 8.1 and / or IBMP 8.3 are prepared wherein one or more PEP2 antigens are inserted in suitable locations on both the IBMP 8.1 and 8.3 antigens that will improve the accuracy and sensitivity of immunoassay testing to detect the presence or absence of antibodies against Trypanosoma cruzi. In certain specific embodiments, there is one PEP2 antigen inserted into the chimeric 8.1 and / or 8.3 antigen, and in other embodiments, there are two or more PEP2 antigens. For example, with regard to the modified chimeric antigen, in certain embodiments, the modified 8.3 antigen of the invention may have the following sequence reflecting the insertion of one PEP2 antigen into the chimeric antigen: In other exemplary embodiments, the modified 8.3 antigen of the invention may have two or more PEP2 antigens inserted in the IBMP chimeric antigen as shown in the following exemplary sequences: ( ) In all of the above specific embodiments, the modified IBMP 8.3 antigens may be combined with a modified IBMP 8.1 antigen as described herein, optionally along with an unmodified chimeric IBMP 8.4 antigen, and the modified chimeric antigen in accordance with the invention can be used in improved diagnostic methods and immunoassays used for the determination of the presence of T. cruzi antibodies in a human or animal subject. The information related to the sequences disclosed herein is summarized in the form below. In addition, an electronic ST26 xml version of this sequence listing is also being submitted herewith.
[0002]
Claims
CLAIMS What is claimed is:
1. A chimeric antigen comprising a modified IBMP 8.1 antigen and / or a modified IBMP 8.3 antigen, wherein the modified IBMP 8.1 and / or 8.3 antigens contain at least one PEP2 antigen.
2. The chimeric antigen according to claim 1 wherein the modified IBMP 8.1 antigen has amino acid sequence SEQ ID NO:
1.
3. The chimeric antigen according to claim 1 wherein the modified IBMP 8.3 antigen has amino acid sequence SEQ ID NO:
3.
4. The chimeric antigen according to claim 1 wherein the modified IBMP 8.1 antigen has an amino acid sequence selected from the group consisting of SEQ ID NO: 1 and SEQ ID NO:
2.
5. The chimeric antigen according to claim 1 wherein the modified IBMP 8.3 antigen has an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO:
6.
6. The chimeric antigen according to claim 1 wherein the modified IBMP 8.1 antigen contains a plurality of PEP2 antigens.
7. The chimeric antigen according to claim 1 wherein the modified IBMP 8.3 antigen contains a plurality of PEP2 antigens.
8. The chimeric antigen according to claim 1 further comprising an unmodified IBMP 8.4 antigen.
9. The chimeric antigen according to claim 8 wherein the unmodified IBMP 8.4 antigen has the amino acid sequence of SEQ ID NO: 8.
10. The chimeric antigen according to claim 1 wherein the at least one PEP2 antigen has the amino acid sequence of SEQ ID NO:
7.
11. The chimeric antigen according to claim 1 wherein the chimeric antigen comprises a modified IBMP 8.1 antigen and an unmodified IBMP 8.3 antigen.
12. The chimeric antigen according to claim 11 wherein the unmodified IBMP 8.3 antigen has sequence SEQ ID NO:
10.
13. The chimeric antigen according to claim 1 wherein the chimeric antigen comprises a modified IBMP 8.3 antigen and an unmodified IBMP 8.1 antigen.
14. The chimeric antigen according to claim 8 wherein the unmodified IBMP 8.1 antigen has sequence SEQ ID NO:
9.
15. A chimeric antigen for diagnosing a Chagas disease infection, said chimeric antigen comprising a modified IBMP 8.1 antigen and a modified IBMP 8.3 antigen, wherein the modified IBMP 8.1 and 8.3 antigens contain at least one PEP2 antigen 16. The chimeric antigen according to claim 15 wherein the modified IBMP 8.1 antigen has the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO:
2.
17. The chimeric antigen according to claim 15 wherein the modified IBMP 8.3 antigen has the amino acid sequence of SEQ ID NO:
3.
18. The chimeric antigen according to claim 15 wherein the modified IBMP 8.3 antigen has the amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO:
6.
19. The chimeric antigen according to claim 15 further comprising an unmodified IBMP 8.4 antigen.
20. The chimeric antigen according to claim 19 wherein the unmodified IBMP 8.4 antigen has the amino acid sequence of SEQ ID NO: 8.
21. A chimeric antigen for diagnosing a Chagas disease infection, said chimeric antigen comprising a modified IBMP 8.1 antigen, a modified IBMP 8.3 antigen, and an unmodified IBMP 8.4 antigen, wherein the modified IBMP 8.1 and 8.3 antigens contain at least one PEP2 antigen.
22. The chimeric antigen according to claim 21 wherein the modified IBMP 8.1 antigen has the amino acid sequence of SEQ ID NO:
1.
23. The chimeric antigen according to claim 21 wherein the modified IBMP 8.3 antigen has the amino acid sequence of SEQ ID NO:
2.
24. The chimeric antigen according to claim 21 wherein the unmodified IBMP 8.4 antigen has the amino acid sequence of SEQ ID NO:
6.
25. A chimeric antigen for use in diagnosing a Chagas disease infection, said chimeric antigen comprising a modified IBMP 8.1 antigen and a modified IBMP 8.3 antigen, wherein the modified IBMP 8.1 and 8.3 antigens contain at least one PEP2 antigen and an antigen selected from the group consisting of 1F8, rTc24 (PGR24-His), TcF, SAPA, TSSA, SAPA / TSSA, SAPA / TSSA, FRA, B13, MACH (PEP2, TcD, TcE, SAPA), TcD, and TcE antigens.
26. The chimeric antigen according to claim 25 wherein the modified IBMP 8.1 antigen has the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO:
2.
27. The chimeric antigen according to claim 25 wherein the modified IBMP 8.3 antigen has the amino acid sequence of SEQ ID NO:
3.
28. The chimeric antigen according to claim 25 wherein the modified IBMP 8.3 antigen has the amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6.
29. The chimeric antigen according to claim 25 wherein the second antigen has a sequence selected from the group consisting of SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:
14.
30. A chimeric antigen for use in diagnosing a Chagas disease infection, said chimeric antigen comprising a modified IBMP 8.1 antigen, a modified IBMP 8.3 antigen, and an unmodified IBMP 8.4 antigen, wherein the modified IBMP 8.1 and 8.3 antigens contain at least one PEP2 antigen and a second antigen selected from the group consisting of 1F8, rTc24 (PGR24-His), TcF, SAPA, TSSA, SAPA / TSSA, SAPA / TSSA, FRA, B13, MACH (PEP2, TcD, TcE, SAPA), TcD, and TcE antigens.
31. The chimeric antigen according to claim 30 wherein the modified IBMP 8.1 antigen has the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO:
2.
32. The chimeric antigen according to claim 30 wherein the modified IBMP 8.3 antigen has the amino acid sequence of SEQ ID NO:
3.
33. The chimeric antigen according to claim 30 wherein the unmodified IBMP 8.4 antigen has the amino acid sequence of SEQ ID NO:
8.
34. The chimeric antigen according to claim 30 wherein the second antigen has a sequence selected from the group consisting of SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:
14.
35. An immunoassay for detecting the presence or absence of antibodies against Trypanosoma cruzi, said immunoassay comprising the chimeric antigen of claim 1 and immunobinding detection reagents which provide a signal that indicates immunobinding when an antibody against Trypanosoma cruzi binds with said chimeric antigen.
36. The immunoassay according to claim 35 wherein the modified IBMP 8.1 antigen has amino acid sequence SEQ ID NO: 1.
37. The immunoassay according to claim 35 wherein the modified IBMP 8.3 antigen has amino acid sequence SEQ ID NO:
3.
38. The immunoassay according to claim 35 wherein the modified IBMP 8.3 antigen has an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO:
6.
39. The immunoassay according to claim 35 wherein the chimeric antigen comprises a modified IBMP 8.1 antigen and an unmodified IBMP 8.3 antigen.
40. The chimeric antigen according to claim 39 wherein the unmodified IBMP 8.3 antigen has sequence SEQ ID NO:
10.
41. The chimeric antigen according to claim 35 wherein the chimeric antigen comprises a modified IBMP 8.3 antigen and an unmodified IBMP 8.1 antigen.
42. The chimeric antigen according to claim 41 wherein the unmodified IBMP 8.1 antigen has sequence SEQ ID NO:
10.
43. The immunoassay according to claim 35 wherein the immunoassay is selected from the group consisting of lateral flow immunoassay, multiple antigen blot assay, direct or indirect Enzyme-linked immunosorbent assay (ELISA), enzymatic immunoassay, sandwich assay, electrochemilumescence assay, dipstick immunoassay, and radioisotope assay.
44. The immunoassay according to claim 35 wherein the immunoassay is a lateral flow immunoassay.
45. An immunoassay for detecting the presence or absence of antibodies against Trypanosoma cruzi, said immunoassay comprising the chimeric antigen of claim 21 and immunobinding detection reagents which provide a signal that indicates immunobinding when an antibody against Trypanosoma cruzi binds with said chimeric antigen.
46. The immunoassay according to claim 45 wherein the immunoassay is selected from the group consisting of lateral flow immunoassay, multiple antigen blot assay, direct or indirect Enzyme-linked immunosorbent assay (ELISA), enzymatic immunoassay, sandwich assay, electrochemilumescence assay, dipstick immunoassay, and radioisotope assay.
47. The immunoassay according to claim 45 wherein the immunoassay is a lateral flow immunoassay.
48. A lateral flow immunoassay for detecting the presence or absence of antibodies against Trypanosoma cruzi, said immunoassay comprising the chimeric antigen of claim 1 and immunobinding detection reagents which provide a signal that indicates immunobinding when an antibody against Trypanosoma cruzi binds with said chimeric antigen.
49. The lateral flow immunoassay according to claim 40 wherein the modified IBMP 8.1 antigen has the amino acid sequence of SEQ ID NO:
1.
50. The lateral flow immunoassay according to claim 48 wherein the modified IBMP 8.3 antigen has the amino acid sequence of SEQ ID NO:
3.
51. The immunoassay according to claim 48 wherein the chimeric antigen comprises a modified IBMP 8.1 antigen and an unmodified IBMP 8.3 antigen.
52. The chimeric antigen according to claim 48 wherein the chimeric antigen comprises a modified IBMP 8.3 antigen and an unmodified IBMP 8.1 antigen.
53. A lateral flow immunoassay for detecting the presence or absence of antibodies against Trypanosoma cruzi, said immunoassay comprising the chimeric antigen of claim 21 and immunobinding detection reagents which provide a signal that indicates immunobinding when an antibody against Trypanosoma cruzi binds with said chimeric antigen.
54. The lateral flow immunoassay according to claim 53 wherein the modified IBMP 8.1 antigen has the amino acid sequence of SEQ ID NO: 1.
55. The chimeric antigen according to claim 53 wherein the modified IBMP 8.3 antigen has the amino acid sequence of SEQ ID NO:
3.
56. The chimeric antigen according to claim 53 wherein the unmodified IBMP 8.4 antigen has the amino acid sequence of SEQ ID NO:
8.
57. An immunoassay method for detecting the presence or absence of antibodies against Trypanosoma cruzi in a human or animal subject, said method comprising: a. providing the chimeric antigen of claim 1; b. obtaining a sample of a bodily fluid or other biological matrix from the subject; c. contacting said sample with said chimeric antigen; and d. determining the presence or absence of antibodies against Trypanosoma cruzi by detecting immunobinding of said chimeric antigen to Trypanosoma cruzi im sa1d sample.
58. The immunoassay method according to claim 57 wherein the immunoassay is selected from the group consisting of lateral flow immunoassay, multiple antigen blot assay, direct or indirect Enzyme-linked immunosorbent assay (ELISA), enzymatic immunoassay, sandwich assay, electrochemilumescence assay, dipstick immunoassay, and radioisotope assay.
59. An immunoassay method for detecting the presence or absence of antibodies against Trypanosoma cruzi in a human or animal subject, said method comprising: a. providing the chimeric antigen of claim 21; b. obtaining a sample of a bodily fluid or other biological matrix from the subject; c. contacting said sample with said chimeric antigen; and d. determining the presence or absence of antibodies against Trypanosoma cruzi by detecting immunobinding of said chimeric antigen to Trypanosoma cruzi im sa1d sample.
60. The immunoassay method according to claim 59 wherein the immunoassay is selected from the group consisting of lateral flow immunoassay, multiple antigen blot assay, direct or indirect Enzyme-linked immunosorbent assay (ELISA), enzymatic immunoassay, sandwich assay, electrochemilumescence assay, dipstick immunoassay, and radioisotope assay.
61. The immunoassay method according to claim 59 wherein the immunoassay is a differential phase-contrast BioCD biosensor.
62. An immunoassay method for diagnosing a Chagas disease infection in a human or animal subject, said method comprising: a. providing the chimeric antigen of claim 1; b. obtaining a sample of a bodily fluid or other biological matrix from the subject; c. contacting said sample with said chimeric antigen; and d. determining the presence or absence of antibodies against Trypanosoma cruzi by detecting immunobinding of said chimeric antigen to Trypanosoma cruzi im sa1d sample.
63. The immunoassay method according to claim 62 wherein the immunoassay is selected from the group consisting of lateral flow immunoassay, multiple antigen blot assay, direct or indirect Enzyme-linked immunosorbent assay (ELISA), enzymatic immunoassay, sandwich assay, electrochemilumescence assay, dipstick immunoassay, and radioisotope assay.
64. An immunoassay method for diagnosing a Chagas disease infection in a human or animal subject, said method comprising: a. providing the chimeric antigen of claim 21; b. obtaining a sample of a bodily fluid or other biological matrix from the subject; c. contacting said sample with said chimeric antigen; and d. determining the presence or absence of antibodies against Trypanosoma cruzi by detecting immunobinding of said chimeric antigen to Trypanosoma cruzi im sa1d sample.
65. A lateral flow immunoassay method for detecting the presence or absence of antibodies against Trypanosoma cruzi in a human or animal subject, said method comprising: a. providing the chimeric antigen of claim 1; b. obtaining a sample of a bodily fluid or other biological matrix from the subject; c. contacting said sample with said chimeric antigen; and d. determining the presence or absence of antibodies against Trypanosoma cruzi by detecting immunobinding of said chimeric antigen to Trypanosoma cruzi im sa1d sample.
66. A lateral flow immunoassay method for detecting the presence or absence of antibodies against Trypanosoma cruzi in a human or animal subject, said method comprising: a. providing the chimeric antigen of claim 21; b. obtaining a sample of a bodily fluid or other biological matrix from the subject; c. contacting said sample with said chimeric antigen; and d. determining the presence or absence of antibodies against Trypanosoma cruzi by detecting immunobinding of said chimeric antigen to Trypanosoma cruzi im sa1d sample.
67. A lateral flow immunoassay method for diagnosing a Chagas disease infection in a human or animal subject, said method comprising: a. providing the chimeric antigen of claim 1; b. obtaining a sample of a bodily fluid or other biological matrix from the subject; c. contacting said sample with said chimeric antigen; and d. determining the presence or absence of antibodies against Trypanosoma cruzi by detecting immunobinding of said chimeric antigen to Trypanosoma cruzi im sa1d sample.
68. A lateral flow immunoassay method for diagnosing a Chagas disease infection in a human or animal subject, said method comprising: a. providing the chimeric antigen of claim 21; b. obtaining a sample of a bodily fluid or other biological matrix from the subject; c. contacting said sample with said chimeric antigen; and d. determining the presence or absence of antibodies against Trypanosoma cruzi by detecting immunobinding of said chimeric antigen to Trypanosoma cruzi im sa1d sample.
69. A test strip for qualitatively determining the present or absence of antibodies against Trypanosoma cruzi, said test strip comprising the chimeric antigen of claim 1 and immunobinding detection reagents on said test strip which provide a signal that indicates immunobinding of the antigens when the sample contains antibodies against Trypanosoma cruzi.
70. The test strip according to claim 69 wherein the test strip is made of a nitrocellulose membrane 71. A test strip for qualitatively determining the present or absence of antibodies against Trypanosoma cruzi, said test strip comprising the chimeric antigen of claim 21 and immunobinding detection reagents on said test strip which provide a signal that indicates immunobinding of the antigens when the sample contains antibodies against Trypanosoma cruzi.
72. The test strip according to claim 71 wherein the test strip is made of a nitrocellulose membrane 73. A device for conducting an immunoassay of antibodies against T. cruzi, said device comprising a test strip that is pre-coated with the chimeric antigen of claim 1 and a detection reagent that detects binding between said chimeric antigen and an antibody against T. cruzi located in a bodily fluid or other biological matrix sample obtained from a subject74. The device according to claim 73 wherein the test strip comprises a nitrocellulose membrane 75. The device according to claim 73 wherein said detection reagents generate a signal when binding is detected.
76. The device according to claim 75 wherein the signal is selected from the group consisting of a colorimetric signal, a fluorescent signal, a chemiluminescent signal, a radioactive signal, and a visual signal.
77. A test kit for qualitatively detecting the presence or absence of antibodies against Trypanosoma cruzi in a sample of bodily fluid or other biological matrix from a human or animal, said test kit comprising: a. a test strip containing the chimeric antigen of claim 1; b. immunobinding detection reagents on said test strip which provide a signal indicative of immunobinding of said chimeric antigen when the sample contains antibodies against Trypanosoma cruzi ; and c. a detection zone on said test strip wherein the signal indicative of immunobinding of said chimeric antigen on the test strip and Trypanosoma cruzi antibodies in the sample can be observed.
78. The test kit according to claim 77 wherein the sample is selected from the group consisting of a bodily fluid, serum, whole blood, saliva, and other biological matrices.
79. A test kit for qualitatively detecting the presence or absence of antibodies against Trypanosoma cruzi in a sample of bodily fluid or other biological matrix from a human or animal, said test kit comprising: a. a test strip containing the chimeric antigen of claim 21; b. immunobinding detection reagents on said test strip which provide a signal indicative of immunobinding of said chimeric antigen when the sample contains antibodies against Trypanosoma cruzi ; andc. a detection zone on said test strip wherein the signal indicative of immunobinding of said chimeric antigen on the test strip and Trypanosoma cruzi antibodies in the sample can be observed.
80. The test kit according to claim 79 wherein the sample is selected from the group consisting of a bodily fluid, serum, whole blood, saliva, and other biological matrices.
81. An immunoassay system for qualitatively detecting the presence or absence of antibodies against Trypanosoma cruzi in a human or animal subject said system comprising: a. a test strip having the chimeric antigen of claim 1; b. a sample of bodily fluid or other biological matrix from the human or animal subject that can be applied to said test strip; c. immunobinding detection reagents on said test strip which provide a signal that indicates immunobinding of the antigens when the sample contains antibodies against Trypanosoma cruzi, and d. a detection zone on said test strip wherein the signal indicative of immunobinding between the antigens on the test strip and antibodies against Trypanosoma cruzi can be observed; 82. The immunoassay system according to claim 81 wherein the signal Is selected from the group consisting of a colorimetric signal, a fluorescent signal, a chemiluminescent signal, a radioactive signal, and a visual signal.
83. The immunoassay system according to claim 81 wherein the test strip is a nitrocellulose membrane.
84. The immunoassay system according to claim 81 wherein the sample is selected from the group consisting of a bodily fluid, serum, whole blood, saliva, and other biological matrices.
85. An immunoassay system for qualitatively detecting the presence or absence of antibodies against Trypanosoma cruzi in a human or animal subject said system comprising:a. a test strip having the chimeric antigen of claim 21; b. a sample of bodily fluid or other biological matrix from the human or animal subject that can be applied to said test strip; c. immunobinding detection reagents on said test strip which provide a signal that indicates immunobinding of the antigens when the sample contains antibodies against Trypanosoma cruzi, and d. a detection zone on said test strip wherein the signal indicative of immunobinding between the antigens on the test strip and antibodies against Trypanosoma cruzi can be observed; 86. The immunoassay system according to claim 85 wherein the signal Is selected from the group consisting of a colorimetric signal, a fluorescent signal, a chemiluminescent signal, a radioactive signal, and a visual signal.
87. The immunoassay system according to claim 85 wherein the test strip is a nitrocellulose membrane.
88. The immunoassay system according to claim 85 wherein the sample is selected from the group consisting of a bodily fluid, serum, whole blood, saliva, and other biological matrices.
Citation Information
Patent Citations
Methods for the detection and diagnosis of Trypanosoma cruzi infection
US20080096232A1
Lateral flow assay system and methods for its use
US20100330585A1
Diagnostic assay for trypanosoma cruzi infection
US20120316209A1
Antigen composition for detecting chagas disease
US20170248597A1
